Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

St Jude Medical begins clinical study of deep brain stimulation for treating depression

St Jude Medical : 08 February, 2008  (New Product)
St Jude Medical has received an Investigational Device Exemption (IDE) from the US Food and Drug Administration (FDA) to begin enrollment in a controlled, multi-site, blinded, clinical study of deep brain stimulation for major depressive disorder, a severe form of depression.
The Broaden ((BROdmann Area 25 DEep brain Neuromodulation) study will evaluate the safety and effectiveness of deep brain stimulation in patients with depression for whom currently available treatments are not effective.

The study will build upon the pioneering depression work of a research team from the University of Toronto, led by neurologist Helen S Mayberg, MD (now with Emory University School of Medicine), and neurosurgeon Andres Lozano, MD.

'Major depressive disorder is severely disabling,' said Dr Lozano. 'Currently, there are no widely-accepted treatment options for patients with this condition once multiple medications, psychotherapy and electroconvulsive therapy have failed.'

Drs Mayberg and Lozano conducted the first study of deep brain stimulation (DBS) for depression in Toronto, Canada, in 2003 and published their findings in Neuron in March 2005. As reported in the journal article, imaging studies led them to an area of the brain thought to be involved in depression called Brodmann Area 25. This area appears to become overactive when people are profoundly sad and depressed.

St Jude Medical owns the intellectual property rights and has various patents pending for the use of neurostimulation at Brodmann Area 25. The Libra Deep Brain Stimulation System, which is being evaluated in the study, is designed to deliver mild electrical pulses from a device implanted near the collarbone and connected to small electrical leads placed at specific targets in the brain.

In the USA more than 21 million adults suffer from some kind of depressive disorder, according to the National Institute of Mental Health. Of these, only about 80 percent can be effectively treated with currently available therapies, according to the National Advisory Mental Health Council. Unfortunately, that means approximately four million adult Americans live with depression that does not respond to medications, psychotherapy and, in certain cases, electroconvulsive therapy.

'St Jude Medical is dedicated to researching and developing neuromodulation therapies for people who live with conditions such as severe depression,' said Chris Chavez, president of St Jude Medical's ANS Division. 'We are hopeful that this trial will lead to the successful development of a sustainable therapy for those patients who have exhausted other treatment options.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo